For over a decade, we have continuously integrated insights from the mast cell disease community to drive possibilities for better outcomes for people impacted by systemic mastocytosis. Our time at #AAAAI25 this month was no different, helping to deepen our commitment to innovation across allergic and inflammatory disorders and demonstrating how we put Patients First.
